Experimental heart medication fails in late trials
Ayonis Pharmaceuticals and Novartis announced that the investigational drug Pelacarsen, aimed at lowering levels of the cholesterol-carrying particle (lipoprotein A) in heart disease patients, failed to achieve its primary goal of reducing the risk of death, heart attacks, or strokes compared to a placebo in late-stage trials. Although the drug significantly reduced protein levels, it did not decrease the risk of cardiovascular disease, causing the company's shares to drop by 6% after market close. These results are significant because they pertain to Novartis's long-term growth drivers, as the company has experimental medicines with potential sales exceeding $10 billion.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)